Interesting post narmac.
Interesting chart as well.
- 2017 - range from $1 to $2.65 USD
- 2018 - a little above $1
- 2019 - gradual increase to about $3 at the end of the year
- 2020 - from $4.22 down to $3.08 near the end of the year when the share took off
- 2021 - Feb 12 $20.28 then declined to approx $5
- 2022 - declined to $4.35 on Apr 1 then shot got up to $10.01 on Apr 12
I have only done a superficial analysis at this stage but reading the article in OncLive their research seems very early at this stage. They seem far behind the research on zen3694. From what I gathered from this article sabizabulin has only been tested in a 1b and phase 2 trial on very small samples of patients.
Once again it seems almost remarkable that Vera is trading at $10USD while ZCC trades at $.15C OTC even though zen3694 is far more advanced in it's trials and is partially financially supported by the NIH and NCI in the USA.
ZCC's management's inability to create shareholder value is almost stunning.
That was a good eye opener narmac. Thanks.
Toinv
